Indication
Recurrent High Grade Glioma
5 clinical trials
6 products
Product
CD200AR-LClinical trial
Phase I Trial: CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy With Adjuvant Reirradiation for Recurrent High-Grade Glioma and Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2025-09-15
Product
CerebracaClinical trial
The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
MVR-C5252Clinical trial
A Phase I Study of Metronomic Temozolomide With Abexinostat (PCI-24781) for Patients With Recurrent High Grade GliomaStatus: Recruiting, Estimated PCD: 2025-02-01
Product
PCI 24781Product
TMZClinical trial
Study on Precision Treatment Strategy Through PTCs (Patient-derived Tumor-like Cell Clusters)-Based Drug Screening for Recurrent High-grade GliomasStatus: Recruiting, Estimated PCD: 2024-08-10